Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 13, 2013 - Issue 10
Submit an article Journal homepage
553
Views
37
CrossRef citations to date
0
Altmetric
Theme: General - Review

The influence of pH and hypoxia on tumor metastasis

Mariam AbazaDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Kuwait University, PO Box 24923, Safat 13110, Kuwait
&
Yunus A LuqmaniDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Kuwait University, PO Box 24923, Safat 13110, KuwaitCorrespondence[email protected] [email protected]
Pages 1229-1242 | Published online: 10 Jan 2014

References

  • Bennewith KL, Dedhar S. Targeting hypoxic tumor cells to overcome metastasis. BMC Cancer 11, 504–509 (2011).
  • Robey IF, Baggett BK, Kirkpatrick ND et al. Bicarbonate increases tumor pH and inhibits spontaneous metastasis. Cancer Res. 69(6), 2260–2268 (2009).
  • Lu P, Weave VM, Werb Z. The extracellular matrix: A dynamic niche in cancer progression. J. Cell Biol. 196(4), 395–406 (2012).
  • Lunt SJ, Fyles A, Hill RP, Milosevic M. Interstitial fluid pressure in tumors: therapeutic barrier and biomarker of angiogenesis. Future Oncol. 4(6), 793–802 (2008).
  • Iessi E, Marino ML, Lozupone F, Fais S, De Milito A. Tumor acidity and malignancy: novel aspects in the design of anti-tumor therapy. Cancer Ther. 6, 55–66 (2008).
  • Yeluri S, Madhok BM, Jayne DG. New horizons in cancer therapy: manipulating tumor metabolism. Biomed. Res. 23, SI 17–23 (2012).
  • Cairns R, Papandreou I, Denko N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol. Cancer Res. 4(2), 61–70 (2006).
  • Hashim AI, Zhang X, Wojtkowiak JW, Martinez GV, Gillies RJ. Imaging pH and metastasis. NMR Biomed. 24(6), 582–591(2011).
  • Calorini L, Peppicelli S, Bianchini F. Extracellular acidity as favoring factor of tumor progression and metastatic dissemination. Exp. Oncol. 34(2), 79–84 (2012).
  • Provent P, Benito M, Hiba B et al. Serial in vivo spectroscopic nuclear magnetic resonance imaging of lactate and extracellular pH in rat gliomas shows redistribution of protons away from sites of glycolysis. Cancer Res. 67(16), 7638–7645 (2007).
  • Song CW, Griffin R, Park HJ. Influence of tumor pH on therapeutic response. In: Cancer Drug Resistance (Cancer Drug Discovery and Development). Teicher BA ( Ed.). Humana Press Inc., NJ, USA, 21–42 (2006).
  • Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 9( Suppl. 5), 10–17 (2004).
  • Hong SS, Lee H, Kim KW. HIF-1alpha: a valid therapeutic target for tumor therapy. Cancer Res. Treat. 36(6), 343–353 (2004).
  • Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell Biol. 12(12), 5447–5454 (1992).
  • Berra E, Pages G, Pouyssegur J. MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev. 19(1–2), 139–145 (2000).
  • Krishnamachary B, Berg-Dixon S, Kelly B et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res. 63(5), 1138–1143.
  • Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vapuel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56(19), 4509–4515 (1996).
  • Degenhardt K, Mathew R, Beaudoin B et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation and tumorigenesis. Cancer Cell 10(1), 51–64 (2006).
  • Mathew R, Karp CM, Beaudoin B et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell 137(6), 1062–1075 (2009).
  • White E, DiPaola RS. The double-edged sword of autophagy modulation in cancer. Clin. Cancer Res. 15(17), 5308–5316 (2009).
  • Yang ZJ, Chee CE, Huang S, Sinicrope FA. The role of autophagy in cancer: therapeutic implications. Mol. Cancer Ther. 10(9), 1533–1541 (2011).
  • Lugini L, Matarrese P, Tinari A et al. Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res. 66(7), 3629–3638 (2006).
  • Fais S. Cannibalism: A way to feed on metastatic tumors. Cancer Lett. 258(2), 155–164 (2007).
  • Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324(5930), 1029–1033 (2009).
  • Semenza GL. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin. Cancer Biol. 19(1), 12–16 (2009).
  • Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 3(3), 187–197 (2006).
  • Lu CW, Lin SC, Chen KF, Lai YY, Tsai SJ. Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J. Biol. Chem. 283(42), 28106–2814 (2008).
  • Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology and tumor maintenance. Cancer Cell 9(6), 425–434 (2006).
  • Wang R, Dillon CP, ShiL Z et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 35(6), 871–882 (2011).
  • Qing G, Skuli N, Mayes PA et al. Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha. Cancer Res. 70(24), 10351–10361 (2010).
  • Singh PK, Mehla K, Hollingsworth MA, Johnson KR. Regulation of aerobic glycolysis by microRNAs in cancer. Mol. Cell Pharmacol. 3(3), 125–134 (2011).
  • Taguchi A, Yanagisawa K, Tanaka M et al. Identification of hypoxia-inducible factor-1 alpha as a novel target for miR-17-92 microRNA cluster. Cancer Res. 68(14), 5540–5545 (2008).
  • Sennoune SR, Luo D, Martinez-Zaguilan R. Plasmalemmal vacuolar-type H+-ATPase in cancer biology. Cell Biochem. Biophys. 40(2), 185–206 (2004).
  • Gristein S, Rothstein S. Mechanisms of regulation of the Na+/H+ exchanger. J. Membrane Biol. 90(1), 1–12 (1986).
  • Frelin C, Vigne P, Ladoux A, Lazdunski M. The regulation of the intracellular pH in cells from vertebrates. Eur. J. Biochem. 174(1), 3–14 (1988).
  • Theroux P, Chaitman BR, Danchin N et al. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high- risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investigators. Circulation 102(25), 3032–3038 (2000).
  • Pinheiro C, Reis RM, Ricardo S, Longatto-Filho A, Schmitt F, BaltazaR F. Expression of monocarboxylate transporters 1, 2 and 4 in human tumors and their association with CD147 and CD44. J. Biomed. Biotechnol. 2010, 1–7 (2010).
  • Le Floch R, Chiche J, Marchiq I et al. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc. Natl Acad. Sci. USA 108(40), 16663–16668 (2011).
  • Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 49(16), 4373–4384 (1989).
  • Neri D, Supuran CT. Interfering with pH regulation in tumors as a therapeutic strategy. Nat. Rev. Drug Discov. 10(10), 767–777 (2011).
  • Lou Y, McDonald PC, Oloumi A et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res. 71(9), 3364–3376 (2011).
  • Lee AH, Tannock IF. Heterogeneity of intracellular pH and of mechanisms that regulate intracellular pH in populations of cultured cells. Cancer Res. 58(9), 1901–1908 (1998).
  • Cheng XF, Wu RH. MR-based methods for pH measurement in brain tumors: current status and clinical potential. In: Diagnostic Techniques and Surgical Management of Brain Tumors. Abujamra Al ( Ed.). InTech, Rijecka, Croatia, 287–302 (2011).
  • Schwiening CJ. Measurement of intracellular pH: a comparison between ion- sensitive microelectrodes and fluorescent dyes. In: Regulation of Tissue pH in Plants and Animals: A Reappraisal of Current Techniques. Egginton S, Taylor EW, Raven JA ( Eds). Cambridge University Press, Cambridge, UK, 1–18 (1999).
  • Han J, Burgess K. Fluorescent indicators for intracellular pH. Chem. Rev. 110(5), 2709–2728 (2010).
  • Rink TJ, Tsien RY, Pozzan T. Cytoplasmic pH and free Mg2+ in lymphocytes. J. Cell Biol. 95(1), 189–196 (1982).
  • Rofstad EK, Mathiesen B, Kindem K, Galappathi K. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res. 66(13), 6699–6707 (2006).
  • Hinton A, Sennoune SR, Bond S et al. Function of a subunit isoforms of the V-ATPase in pH homeostasis and in vitro invasion of MDA-MB231 human breast cancer cells. J. Biol. Chem. 284(24), 16400–16408 (2009).
  • Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J. Nucl. Med. 49( Suppl. 49), 24S–42S (2008).
  • Glunde K, Guggino SE, Solaiyappan M, Pathak AP, Ichikawa Y, Bhujwalla ZM. Extracellular acidification alters lysosomal trafficking in human breast cancer cells. Neoplasia 5(6), 533–545 (2003).
  • Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 39(3), 305–318 (2007).
  • Al Saleh S, Sharaf LH, Luqmani YA. Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review). Int. J. Oncol. 38(5), 1197–1217 (2011).
  • Ward C, Langdon SP, Mullen P et al. New strategies for targeting the hypoxic tumor microenvironment in breast cancer. Cancer Treat. Rev. 39(2), 171–179 (2013).
  • Fischer K, Hoffmann P, Voelkl S et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109(9), 3812–3819 (2007).
  • Fischer B, Muller B, Fisch P, Kreutz W. An acidic microenvironment inhibits anti-tumoral non-major histocompatibility complex-restricted cytotoxicity: implications for cancer immunotherapy. J. Immunother. 23(2), 196–207 (2000).
  • Dietl K, Renner K, Dettmer K et al. Lactic acid and acidification inhibit TNF secretion and glycolysis of human monocytes. J. Immunol. 184(3), 1200–1209 (2010).
  • Park HJ, Lee SH, Chung H et al. Influence of environmental pH on G2-phasearrest caused by ionizing radiation. Radiat. Res. 159(1), 86–93 (2003).
  • Jahde E, Glusenkamp KH, Klunder I, Hulser DF, Tietze LF, Rajewsky MF. Hydrogen ion-mediated enhancement of cytotoxicity of bis-chloroethylating drugs in rat mammary carcinoma cells in vitro. Cancer Res. 49(11), 2965–2972 (1989).
  • Mahoney BP, Raghunand N, Baggett B. Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem. Pharmacol. 66(7), 1207–1218 (2003).
  • Ferguson PJ, Phillips JR, Selner M, Cass CE. Differential activity of vincristine and vinblastine against cultured cells. Cancer Res. 44(8), 3307–3312 (1984).
  • Koch S, Mayer F, Honecker F, Schittenhelm M, Bokemeyer C. Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumors under normoxic and hypoxic conditions in vitro. Br. J. Cancer 89(11), 2133–2139 (2003).
  • Green SL, Freiberg RA, Giaccia AJ. p21 (Cip1) and p27 (Kip1) regulate cell cycle reentry after hypoxic stress but are not necessary for hypoxia-induced arrest. Mol. Cell Biol. 21(4), 1196–1206 (2001).
  • Graeber TG, Osmanian C, Jacks T et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379(6560), 88–91 (1996).
  • McCarty MF, Whitaker J. Manipulating tumor acidification as a cancer treatment strategy. Altern. Med. Rev. 15(3), 264–272 (2010).
  • Lu X, Qin W, Li J et al. The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump. Cancer Res. 65(15), 6843–6849 (2005).
  • Wu YC, Wu WK, Li Y et al. Inhibition of macroautophagy by bafilomycin A1 lowers proliferation and induces apoptosis in colon cancer cells. Biochem. Biophys. Res. Commun. 382(2), 451–456 (2009).
  • De Milito A, Canese R, Marino ML et al. pH-dependent anti-tumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int. J. Cancer 127(1), 207–219 (2010).
  • Song CW, Lyons JC, Griffin RJ, Makepeace CM, Cragoe EJ Jr. Increase in thermosensitivity of tumor cells by lowering intracellular pH. Cancer Res. 53(7), 1599–1601 (1993).
  • Cho YL, Lee KS, Lee SJ et al. Amiloride potentiates TRAIL-induced tumor cell apoptosis by intracellular acidification-dependent Akt inactivation. Biochem. Biophys. Res. Commun. 326(4), 752–758 (2005).
  • Luciani F, Spada M, De Milito A et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J. Natl Cancer Inst. 96(22), 1702–1713 (2004).
  • Andreev OA, Dupuy AD, Segala M et al. Mechanism and uses of a membrane peptide that targets tumors and other acidic tissues in vivo. Proc. Natl Acad. Sci. USA 104(19), 7893–7898 (2007).
  • Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anti-cancer treatment. Oncogene 25(34), 4633–4646 (2006).
  • De LM, Lorusso V, Latorre A et al. Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study. Eur. J. Cancer 37(3), 364–368 (2001).
  • Maher JC, Krishan A, Lampidis T. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother. Pharmacol. 53(2), 116–122 (2004).
  • Geschwind JF, Georgiades CS, Ko YH, Pedersen PL. Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma. Expert Rev. Anticancer Ther. 4(3), 449–457 (2004).
  • Rapisarda A, Zalek J, Hollingshead M et al. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res. 64(19), 6845–6848 (2004).
  • Robey IF, Martin NK. Bicarbonate and dichloroacetate: evaluating pH altering therapies in a mouse model for metastatic breast cancer. BMC Cancer 11, 235–244 (2011).
  • Bonnet S, Archer SL, Allalunis-Turner J et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11(1), 37–51 (2007).
  • Wong JY, Huggins GS, Debidda M, Munshi NC, De Vivo I. Dichloroacetate induces apoptosis in endometrial cancer cells. Gynecol. Oncol. 109(3), 394–402 (2008).
  • Onnis B, Rapisarda A, Melillo G. Development of HIF-1 inhibitors for cancer therapy. J. Cell Mol. Med. 13(9A), 2780–2786 (2009).
  • Semenza GL. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3(10), 721–732 (2003).
  • Warburton C, Dragowska WH, Gelmon K et al. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin. Cancer Res. 10(7), 2512–2524 (2004).
  • Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G. Anti-tumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol. Cancer Ther. 3(3), 233–244 (2004).
  • Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev. 26(2), 299–310 (2007).
  • Thiry A, Dogne JM, Masereel B, Supuran CT. Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol. Sci. 27(11), 566–573 (2006).
  • Gieling RG, Babur M, Mamnani L et al. Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. J. Med. Chem. 55(11), 5591–5600 (2012).
  • Chen S, Sang N. Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors. J. Biomed. Biotech. 2011, 1–14 (2011).
  • Park KC, Kim SW, Park JH et al. Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo. Cancer Sci. 102(2), 343–350 (2011).
  • Sermeus A, Michiels C. Reciprocal influence of the p53 and the hypoxic pathway. Cell Death Dis. 2(5), 1–11 (2011).
  • Yang J, Ahmed A, Poon E et al. Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia. Mol. Cell Biol. 29(8), 2243–2253 (2009).
  • Liang Y, Besch-Williford C, Benakanakere I, Thorpe PE, Hyder SM. Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors. Breast Cancer Res. Treat. 125(2), 407–420 (2011).
  • Wang H, Yan C. A small-molecule p53 activator induces apoptosis through inhibiting MDMX expression in breast cancer cells. Neoplasia 13(7), 611–619 (2011).
  • Kusuzaki K, Murata H, Matsubara T et al. Acridine orange could be an innovative anticancer agent under photon energy. In Vivo 21(2), 205–214 (2007).
  • Lunt SJ, Telfer BA, Fitzmaurice RJ, Stratford IJ, Williams KJ. Tirapazamine administered as a neoadjuvant to radiotherapy reduces metastatic dissemination. Clin. Cancer Res. 11(11), 4212–4216 (2005).
  • Lalani AS, Alters SE, Wong A, Albertella MR, Cleland JL, Herner WD. Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in pre-clinical models of pancreatic cancer. Clin. Cancer Res. 13(7), 2216–2225 (2007).
  • Jameson MB, Rischin D, Pegram M et al. A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother. Pharmacol. 65(4), 791–801 (2010).
  • Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219(4587), 983–985 (1983).
  • Willet CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10(2), 145–147 (2004).
  • Rakha EA, Chan S. Metastatic triple-negative breast cancer. Clin. Oncol. 23(9), 587–600 (2011).
  • Pietras K. Increasing tumor uptake of anticancer drugs with imatinib. Semin. Oncol. 31(2 Suppl. 6), 18–23 (2004).
  • Pietras K, Stumm M, Hubert M et al. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin. Cancer Res. 9(10 Pt 1), 3779–3787 (2003).
  • Pietras K, Ostman A, Sjoquist M et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 61(7), 2929–2934 (2001).
  • Baranowska-Kortylewicz J, Abe M, Pietras K et al. Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy. Cancer Res. 65(17), 7824–7831 (2005).
  • Khaja M, Al Mohri I, Merlin P, Luqmani YA. Extracellular alkaline pH leads to increased metastatic potential of estrogen receptor silenced endocrine resistant breast cancer cells. PLoS ONE (2013) (In Press).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.